Results 261 to 270 of about 99,136 (277)
Some of the next articles are maybe not open access.
Blood, 2008
AbstractThere has been a remarkable explosion of knowledge into the molecular defects that underlie the acute and chronic leukemias, leading to the introduction of targeted therapies that can block key cellular events essential for the viability of the leukemic cell.
openaire +2 more sources
AbstractThere has been a remarkable explosion of knowledge into the molecular defects that underlie the acute and chronic leukemias, leading to the introduction of targeted therapies that can block key cellular events essential for the viability of the leukemic cell.
openaire +2 more sources
Hypoplastic myelodysplastic syndrome
Cancer, 1988Over a period of 8 years 11 of 64 patients seen at Loyola University Medical Center with the diagnosis of myelodysplastic syndrome (MDS) also exhibited bone marrow hypoplasia (marrow cellularity of 25% or less) at presentation. The other 53 had normocellular or hypercellular marrow.
S, Nand, J E, Godwin
openaire +2 more sources
Childhood Myelodysplastic Syndrome
The Indian Journal of Pediatrics, 2013Myelodysplastic syndrome (MDS) comprises of a heterogeneous group of bone marrow disorders resulting from a clonal stem cell defect characterised by cytopenias despite a relatively hypercellular marrow, ineffective hematopoiesis, morphological dysplasia in the marrow elements, no response to hematinics such as iron, B12 or folic acid and risk of ...
Tathagata, Chatterjee, V P, Choudhry
openaire +2 more sources
Blood Reviews, 1987
The myelodysplastic syndromes constitute a fascinating model for monoclonal premalignant disorders. Haemopoiesis is 'dysplastic' with inefficient maturation of a slowly expanding or sometimes of a stable population, of blood cell precursors. About one third of the patients evolve into acute leukaemia, the result of either a progressive expansion of the
R L, Verwilghen, M A, Boogaerts
openaire +2 more sources
The myelodysplastic syndromes constitute a fascinating model for monoclonal premalignant disorders. Haemopoiesis is 'dysplastic' with inefficient maturation of a slowly expanding or sometimes of a stable population, of blood cell precursors. About one third of the patients evolve into acute leukaemia, the result of either a progressive expansion of the
R L, Verwilghen, M A, Boogaerts
openaire +2 more sources
Myelodysplastic syndrome classification
Annales de biologie clinique, 2013Myelodysplastic syndromes (MDS) are myeloid disorders with various clinical and biological presentations. The French-American-British (FAB-1982) classification included five categories basing on morphology and bone marrow blast count. Three criteria are taken into account: 1) the percentage of blasts in peripheral blood and bone marrow, 2) the ...
Ines, Ghariani +3 more
openaire +2 more sources
Expert Opinion on Biological Therapy, 2007
The myelodysplastic syndrome(s) (MDS), bone marrow stem cell malignancies that share pathogenetic overlap with acute myeloid leukemia, are characterized by peripheral blood cytopenias and, in more advanced subtypes, varied degrees of maturation arrest. Premature apoptosis of bone marrow cellular elements contributes to ineffective hematopoiesis, which ...
openaire +2 more sources
The myelodysplastic syndrome(s) (MDS), bone marrow stem cell malignancies that share pathogenetic overlap with acute myeloid leukemia, are characterized by peripheral blood cytopenias and, in more advanced subtypes, varied degrees of maturation arrest. Premature apoptosis of bone marrow cellular elements contributes to ineffective hematopoiesis, which ...
openaire +2 more sources
Pediatric myelodysplastic syndromes
Current Treatment Options in Oncology, 2005A new classification of myelodysplastic and myeloproliferative diseases in childhood has greatly facilitated the diagnosis of these uncommon disorders. Because hematopoietic stem cell transplantation (HSCT) can cure more than half of the affected children, palliative treatment strategies often applied in adult myelodysplastic syndrome (MDS) are of ...
Niemeyer, Charlotte Marie +2 more
openaire +4 more sources
Myelodysplastic syndrome overview
Seminars in Hematology, 2002Myelodysplastic syndrome (MDS) is a heterogeneous hematopoietic stem cell disorder characterized by bone marrow dysplasia and peripheral cytopenias. Eighty percent of patients found to have MDS are older than 60 years and therefore not eligible for the only potentially curative therapy, bone marrow transplantation.
openaire +2 more sources
Myelodysplastic Syndrome Updated
Pathobiology, 2018This review highlights the main changes in the revised 2016 WHO Classification of Myeloid Neoplasms (published in 2017) that impact the diagnosis and management of patients with myelodysplastic syndrome (MDS). The revision was based on data accumulated since the 2008 WHO classification of MDS, much of which relates to new molecular genetic information ...
openaire +2 more sources